Aim Vaccine Co., Ltd. Class H

World's First Serum-Free Iterative Rabies Vaccine from AIM Successfully Passes On-Site Registration Inspections and Is Imminent for Launch

AIM Vaccine's 20-Valent Pneumococcal Conjugate Vaccine Receives Clinical Approval, Upgraded Iterative Major Product Expected to Seize Domestic Opportunities

AIM's Iterative Process High-Efficiency Diploid Rabies Vaccine Completes Phase III Clinical Trials, Efficacy Significantly Higher than Existing Market Products

AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector

AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S. ,mRNA Platform Advantages Shine Through